An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

A new study has introduced an innovative approach to CAR-T therapy that could address some of the current challenges in ...

Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General ...

Series C financing co-led by Double Point Ventures and DCVC Bio Proceeds to support the clinical development of VivoVec™ derived in vivo CAR T cells SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) -- (Umoja) ...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...